Nasal vaccines represent a promising shift in how we prevent infectious diseases. By building immunity at the body's first line of defence, they could stop infections before they begin, reduce ...

A research team at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel live-attenuated vaccine candidate, cb1, capable of generating broad immunity against a wide ...

An intranasal adjuvanted recombinant influenza vaccine appeared to safely prompt a robust response to a range of H5N1 clades, according to a phase I trial. Immune responses among the three groups that ...

The FluMist vaccine triggers an immune response directly in nasal tissue in adults, researchers reported April 29 in the journal Science Translational Medicine. This immune response stays in the upper ...

Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early phase clinical trial that found an ...

Since it was first detected in the United States in 2014, H5N1 avian influenza, commonly known as bird flu, has jumped from wild birds to farm animals and then to people, causing more than 70 human ...

The use of LuerVax® and Spray Divider™ support Aptar’s commitment to advancing drug delivery and next-generation vaccine development, backed by comprehensive regulatory and technical expertise ...

A vaccine usually trains your immune system to recognize one target. Here, the target is basically “anything that doesn’t belong in the lungs.” That is the surprising promise behind a new mouse study ...

Researchers at WashU Medicine have developed a nasal vaccine against the highly pathogenic H5N1 avian influenza virus, or bird flu, which has jumped from wild birds to livestock to humans. When tested ...

The experimental nasal vaccine developed at Chiba University stimulated strong and long-lasting immune responses in animal models, activating tumor-fighting cells in the cervix and slowing cervical ...

In a phase I trial, an intranasal adjuvanted recombinant influenza vaccine appeared to result in response to a range of H5N1 clades. The adjuvanted vaccine elicited seroconversion against clade 2 ...